Eledon Pharmaceuticals (ELDN) Non-Current Deferred Tax Liability (2020 - 2026)

Eledon Pharmaceuticals has reported Non-Current Deferred Tax Liability for 7 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed 0.18% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (changed 0.18% YoY), and the FY2025 full-year result was $2.2 million, changed 0.18% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $2.2 million, roughly flat from $2.2 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $2.2 million in Q4 2025, with the low at $1.8 million in Q1 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $1.9 million across 5 years, with a median of $1.8 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability tumbled 51.4% — and 2024, when it increased 24.6%.
• Eledon Pharmaceuticals' Non-Current Deferred Tax Liability stood at $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then advanced by 24.6% to $2.2 million in 2024, then increased by 0.18% to $2.2 million in 2025, then changed by 0.0% to $2.2 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.2 million (Q1 2026), $2.2 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.